Business Description
Probi AB
ISIN : SE0001280355
Share Class Description:
LTS:0GZB: Ordinary SharesCompare
Compare
Traded in other countries / regions
PROB.SwedenPBBIF.USA0GZB.UK IPO Date
2016-06-07Description
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.44 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.78 | |||||
| Interest Coverage | 2.09 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 12.43 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.3 | |||||
| 3-Year EBITDA Growth Rate | -16 | |||||
| 3-Year EPS without NRI Growth Rate | -43.3 | |||||
| 3-Year FCF Growth Rate | -32.1 | |||||
| 3-Year Book Growth Rate | 7.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 37.17 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.45 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.04 | |||||
| Quick Ratio | 4.69 | |||||
| Cash Ratio | 3.28 | |||||
| Days Inventory | 108.29 | |||||
| Days Sales Outstanding | 55.41 | |||||
| Days Payable | 26.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 1.07 | |||||
| 3-Year Dividend Growth Rate | 9.1 | |||||
| Shareholder Yield % | 0.67 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 32.88 | |||||
| Operating Margin % | 0.63 | |||||
| Net Margin % | 2.13 | |||||
| FCF Margin % | 4.63 | |||||
| ROE % | 0.96 | |||||
| ROA % | 0.88 | |||||
| ROIC % | 0.36 | |||||
| 3-Year ROIIC % | -59.53 | |||||
| ROC (Joel Greenblatt) % | 3.82 | |||||
| ROCE % | 1.01 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 223.97 | |||||
| Forward PE Ratio | 57.26 | |||||
| PE Ratio without NRI | 223.97 | |||||
| Shiller PE Ratio | 36.92 | |||||
| Price-to-Owner-Earnings | 45.85 | |||||
| PS Ratio | 4.8 | |||||
| PB Ratio | 2.18 | |||||
| Price-to-Tangible-Book | 4.32 | |||||
| Price-to-Free-Cash-Flow | 103.83 | |||||
| Price-to-Operating-Cash-Flow | 35.45 | |||||
| EV-to-EBIT | 184.74 | |||||
| EV-to-EBITDA | 24.01 | |||||
| EV-to-Revenue | 4.26 | |||||
| EV-to-FCF | 96.54 | |||||
| Price-to-Projected-FCF | 1.53 | |||||
| Price-to-Median-PS-Value | 0.79 | |||||
| Price-to-Graham-Number | 6.56 | |||||
| Price-to-Net-Current-Asset-Value | 7.8 | |||||
| Price-to-Net-Cash | 22.31 | |||||
| Earnings Yield (Greenblatt) % | 0.53 | |||||
| FCF Yield % | 1 | |||||
| Forward Rate of Return (Yacktman) % | -8.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Probi AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 642.708 | ||
| EPS (TTM) (kr) | 1.21 | ||
| Beta | 0.27 | ||
| Volatility % | 0.64 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 203 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 203 - 203 | ||
| Shares Outstanding (Mil) | 11.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Probi AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Probi AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Probi AB Frequently Asked Questions
What is Probi AB(LTS:0GZB)'s stock price today?
The current price of LTS:0GZB is kr203.00. The 52 week high of LTS:0GZB is kr203.00 and 52 week low is kr203.00.
When is next earnings date of Probi AB(LTS:0GZB)?
The next earnings date of Probi AB(LTS:0GZB) is 2024-10-22.
Does Probi AB(LTS:0GZB) pay dividends? If so, how much?
Probi AB(LTS:0GZB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers